12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of an oral treatment, BCX4161, in preventing
acute attacks in subjects with hereditary angioedema (HAE). Eligible subjects will be
randomized to receive one of two doses of BCX4161 or placebo for 12 weeks. The study will
compare the number of acute attacks in each treatment group, as well as a number of other
clinical outcomes, and the safety and tolerability of each dose of BCX4161 compared to
placebo.